<DOC>
	<DOC>NCT01844180</DOC>
	<brief_summary>The objective of this study is to explore efficacy, safety and tolerability of ONO-2952 in female subjects with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D).</brief_summary>
	<brief_title>A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>1. Female 1865 years of age (inclusive) 2. Diagnosed with IBS based on the following criteria (Rome III criteria): Symptom onset at least 6 months prior to diagnosis, and Recurrent abdominal pain or discomfort at least 3 days per month for the past 3 months, and Abdominal discomfort or pain associated with two or more of the following at least 25% of the time: 1. Improvement with defecation 2. Onset associated with a change in frequency of stool/defecation 3. Onset associated with a change in form (appearance) of stool 3. Diagnosed with IBSD, defined as loose/watery stools ≥ 25% and hard/lumpy stools ≤ 25% of defecations Any structural abnormality of the gastrointestinal (GI) tract (other than esophagitis or gastritis) History of Crohn's disease, ulcerative colitis, diabetes mellitus, lactose malabsorption, malabsorption syndromes, celiac sprue, or any upper GI symptoms that may impact the assessment of IBS symptoms</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Irritable Bowel Syndrome</keyword>
	<keyword>IBS</keyword>
	<keyword>ONO-2952</keyword>
</DOC>